Souhaitez-vous accéder aux communiqués récents ?

Cannara signs first long-term international supply agreement with Curaleaf, accelerating Valleyfield expansion and entry into global medical markets.

MONTRÉAL, 14 juill. 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (« Cannara », la « Société », « nous ») (TSX: LOVE) (OTCQX : LOVFF) (FRA : 8CB0), producteur verticalement intégré de cannabis...

PANAMA CITY, July 09, 2026 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY) and a leading global medical cannabis company, today announced the...

New Study Demonstrates Significant Symptom Relief for Late-Stage Palliative Patients Treated with Cannabis-based Medicines Bensheim, Germany – 13th June 2025 – According to the World Health...

Neue Studie zeigt positive Ergebnisse bei der Behandlung von Palliativpatient:innen im Spätstadium mit Cannabis-basierten Arzneimitteln Bensheim – 13. Juni 2025. Laut Angaben der WHO benötigen jedes...

Cannabis-Based Therapy Shows Promise in Improving Sleep Quality and Pain Management Bensheim, Germany – 14 March 2025 – In anticipation of World Sleep Day, Avextra has revealed findings from its...

Cannabis-basierte Therapie zeigt vielversprechende Ergebnisse bei der Verbesserung der Schlafqualität und der Schmerzbehandlung Bensheim, Deutschland - 14. März 2025 - Im Vorfeld des Weltschlaftags...

Exclusive Industry Role: Avextra is the industry partner in the first EU-funded project focused on psychedelic-assisted therapy for patients in palliative care suffering from depression, with a total...

Avextra Portugal launches an innovative in-house breeding program to develop proprietary cannabis varieties with specific, consistent and reproducible cannabinoid and terpene profiles.Over a two-year...

The Italian Medicines Agency AIFA and the Italian Ministry of Health have granted formal approval for NEUROBIS; a multi-centre Phase II study to evaluate safety, and efficacy of an Avextra oral...